Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04235621 · ClinicalTrials.gov registry record
A Study to Understand the Genetics and Clinical Course of Focal Segmental Glomerulosclerosis (FSGS), Treatment-Resistant Minimal Change Disease (TR-MCD), and Diabetic Nephropathy (DN)
A clinical trial, sponsored by Goldfinch Bio.
- Terminated
- Registry status
- 20
- Enrollment target
NCT04235621: Clinical Trial study, sponsored by Goldfinch Bio.
NCT04235621 is a clinical trial that was terminated before completion, run by Goldfinch Bio. The registered enrollment target is 20 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04235621 was terminated before completion, sponsored by Goldfinch Bio.
- TERMINATED
- Registry status
- 20 participants
- Enrollment target
Study Summary
This is a study with 2 parts. Part 1 comprises a visit to collect biological samples necessary for the molecular characterization of chronic kidney disease. Part 2 comprises an observational period of 5 visits over a period up to 8 weeks. During Part 2, baseline tests will be conducted, and urine will be collected approximately every 2 weeks for 8 weeks. Patients may participate in Part 1, Part 2, or both, and will be followed for up to 1 year consisting of data collection from the patient's medical records and home collection of urine samples every 4 months.
Interventions
- OTHER FSGS/TR-MCD
- OTHER Diabetic Nephropathy (DN)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2019-12-20 |
| Est. Completion | 2020-05-27 |
Why NCT04235621 stopped before completion
NCT04235621 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 20 participants, a relatively small participant target.
The record links to 0 conditions, and to 2 interventions - of which FSGS/TR-MCD is the first listed.
NCT04235621 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04235621 about?
NCT04235621 is a clinical study titled "A Study to Understand the Genetics and Clinical Course of Focal Segmental Glomerulosclerosis (FSGS), Treatment-Resistant Minimal Change Disease (TR-MCD), and Diabetic Nephropathy (DN)". This is a study with 2 parts. Part 1 comprises a visit to collect biological samples necessary for the molecular characterization of chronic kidney disease. Part 2 comprises an observational period of 5 visits over a period up to 8 weeks. During Part 2, baseline tests will be conducted, and urine wi...
What is the current status of trial NCT04235621?
This trial is currently terminated. The enrollment target is 20 participants. The study started on 2019-12-20. Estimated completion is 2020-05-27.
What interventions are being tested in trial NCT04235621?
The interventions under investigation include: FSGS/TR-MCD (OTHER), Diabetic Nephropathy (DN) (OTHER).
Who is sponsoring clinical trial NCT04235621?
This trial is sponsored by Goldfinch Bio, which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00573339 · 20 participants
Cardiac Magnetic Resonance Imaging (MRI) Normal Reference Control Group Testing
- NCT00692939 · 20 participants · Phase 1
Autologous Stem Cell Transplantation for Crohn's Disease
- NCT00967785 · 20 participants · Phase 1
A Phase I Study of Mozobil in the Treatment of Patients With WHIMS
- NCT01406691 · 20 participants · Phase 4
Light Flashes to Treat Delayed Sleep Phase Disorder (DSPD)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI